Rituximab for the treatment of relapsed or refractory stage III or

lymphoma, having considered evidence on the nature of the condition and the value placed on the benefits of rituximab by people with follicular non-Hodgkin's lymphoma ...

http://www.nice.org.uk/nicemedia/pdf/TA137guidance.pdf